MENORAH MEDICAL CENTER

December 9, 1985

Director, Material Licensing Branch Division of Fuel Cycle and Material Safety United States Nuclear Regulatory Commission - Region III 799 Roosevelt Road Glen Ellyn, Illinois 60137

Re: License #24-01239-01 Expiration March 31, 1988

Dear Sir:

We would like to amend our NRC License, Number 24-01239-01 as follows:

- Please add as user physicians, Anthony G. Bledin, M.D., and Bruce Hoskins, M.D.
- Dr. Hoskins is previously authorized for Group VI under NEC License #24-00889-01 and Teletherapy (Control #77154) under NRC License #24-00889-02.
- 3. Enclosed is a copy of Dr. Bledin's preceptorship statement. He is Board Certified (ABR) with special competence in nuclear medicine.
- Please delete from our license the following individuals: Dr. R.W. Lambie, Dr. Edwin M. Herman, Dr. Frank Victor, Dr.Mordecai Kopperman, Dr. William J. Halleran, III, Dr. Johns Norman Liu, Dr. Walter G. Dukstein and Dr. William E. White.
- 5. Please delete Dr. Dukstein as Radiation Safety Officer and add Dr. Bledin as Radiation Safety Officer.

Sincerely,

MENORAH MEDICAL CENTER

Chick

Ronald C. Glick, D.B.A. Assistant Executive Director

RCG:dt d3030

CONTROL NO. 80321

Enclosure

Austicant ECEIVES DEC 16 1985 REGION III

DEC 1 6 1985

αģ

330

23

-10

N

CEIVE

8604040035 860130 REG3 LIC30 24-01239-01 PDR

EXECUTIVE MANAGEMENT OFFICES FRe-Ibill Road, Kansas City, Missouri 64110 (816) 276-8101

Pano Inro	23
Page Thre	62.

Sec. Sec.	lexas	Depar	tment	of	Heal	th	
PRECEPTO	R STA	TEMENT	FOR	LICE	NSE	APPLI	CATION

0

TRC FORM 41-2a (Rev. 9-77)

The back of this page must be signed by the physician's nuclear medicine preceptor.

NAME AND ADDRESS OF APPLICANT PHYSICIAN	INCLUSIVE DATES TRAINING RECEIVED
Anthony G. Bledin, M.D. Parkway Hospital 233 W Parker, Houston, Texas	April 1, 198 - August 31, 1982
CLINICAL TRAINING AND EXPERIENCE OF PHY	SICIAN WHO WILL USE RADIOACTIVE MATERIAL

ISOTOPE	TYPE OF STUDY OR THERAPY	NUMBER OF CASES OBSERVED *	NUMBER OF CASES INVOLVING ACTIVE PARTICIPATION **
1-123	UPTAKE, DILUTION, AND EXCRETION	ON STUDIES	

An example of the second		1114	1 31
Cr-51		19	
Co-57	Schillings	32	16
I-131	Rose Bengal Liver Function	1	1
And a second sec	Courses designed to determine the second s		
Contraction of the second diversion of the second			
And a state of the			
A REAL PROPERTY OF THE REAL PR	and the second	the second s	

THERAPY PROCEDURES

1-131	Thyroid Therapy - Cancer	91	10
I=1.3.1	Thyroid Therapy - Non-Cancer	8	45
			With the second state of t
			ner finte sen en en else estats est
			A last of the second se
			an a
			A R M R R R R R R R R R R R R R R R R R
and the second second second second second			and and the second s
			ter an
	The second state of the se		the second s
		· · · · · · · · · · · · · · · · · · ·	
		a state of the second state of the second state of the	the second

Continued on page four

CONTROL NO. 00321

ISOTOPE TYPE OF STUDY OR THERAPY NUMBER OF NUMBER OF CASES CASES INVOLVING ACTIVE OBSERVED * PARTICIPATION ** IMAGING AND TUMOR LOCALIZATION STUDIES Te-99m Brain Flow and Scan 47 23 Te-99m Superior vena cava dynamics Study Renal Flow & Scan 98 49 Te-99m 48 24Te-99m Catheter Placement and Flow 68 34 Te-99m Arterial Catheter Study, Hepatic 452 226 Te-99m Arterial Catheter Study, Hypogastric 308 154 Te-99m Biliary Flow Study 31 16 GI Bleeding Te-99m Te-99m Venous Flow Study Thyroid Imaging 123 2461-131 86 43 1-131 Thyroid Cancer Study 48 95 6,288 3.144 Tc-99m Liver/Spleen Se-75 7 Pancreas 1 Bone Imaging - Whole Body Pulmon. Perfusion Imaging 3,340 Te-99m 6.684 Te-99m 263131 2.720 Cardiac Imaging Tc-99m 1,360 Xe-133 Pulmonary Ventilation 181 90 Te-99m 508 Brain Imaging 1,016 Yb-169 Cisternogram Tc-99m Kidney Imaging Ga-67 Tumor Localization 348 144 Te-99m Lymph Node Scan 38 19 Bone Marrow Imaging Whole Body Te-99m 4 Te-99m Cardiac Scan with exercise 23 11 830 * Observation should consist of observing radioisotope administration techniques and discussion with preceptor of case histories.

Page Four

** Active participation should include (a) examination of the patient, (b) recommendation of dosage, (c) collaboration in the calibration and administration of the dose, and (d) followup of patient through treatment period.

TOTAL NUMBER OF HOURS OF PARTICIPATION IN CLINICAL TRAINING 2720 HOURS. TOTAL NUMBER OF HOURS OF CLASSROOM AND LABORATORY TRAINING 1700 HOURS.

I CERTIFY THE ABOVE NAMED PHYSICIAN SUCCESSFULLY COMPLETED THE TRAINING AS SPECIFIED ABOVE.

T.P. Haynie, M.D.		D. Anderson Hospital and Institute, Houston, Tx	F.P. Carmie 60
Name of physician(preceptor)		Institution	Signature

CONTROL NO. 80321